Jaya Sangodkar, Ph.D.
Affiliations: | 2012 | Cancer Biology | Icahn School of Medicine at Mount Sinai, New York, NY, United States |
Area:
Molecular Biology, Cell Biology, Genetics, OncologyGoogle:
"Jaya Sangodkar"Parents
Sign in to add mentor| Goutham Narla | grad student | 2012 | Mount Sinai School of Medicine | |
| (The Role of KLF6 Gene in Lung Cancer.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Rasool RU, O'Connor CM, Das CK, et al. (2023) Loss of LCMT1 and biased protein phosphatase 2A heterotrimerization drive prostate cancer progression and therapy resistance. Nature Communications. 14: 5253 |
| O'Connor CM, Taylor SE, Miller KM, et al. (2021) Targeting ribonucleotide reductase induces synthetic lethality in PP2A-deficient uterine serous carcinoma. Cancer Research |
| Scarpa M, Singh P, Bailey CM, et al. (2021) PP2A-activating drugs enhance FLT3 inhibitor efficacy through AKT inhibition-dependent GSK-3β-mediated c-Myc and Pim-1 proteasomal degradation. Molecular Cancer Therapeutics |
| Noto FK, Sangodkar J, Adedeji BT, et al. (2020) The SRG rat, a Sprague-Dawley Rag2/Il2rg double-knockout validated for human tumor oncology studies. Plos One. 15: e0240169 |
| Coles GL, Cristea S, Webber JT, et al. (2020) Unbiased Proteomic Profiling Uncovers a Targetable GNAS/PKA/PP2A Axis in Small Cell Lung Cancer Stem Cells. Cancer Cell |
| Farrington CC, Yuan E, Mazhar S, et al. (2019) Protein phosphatase 2A activation as a therapeutic strategy for managing MYC-driven cancers. The Journal of Biological Chemistry |
| O'Connor CM, Leonard D, Wiredja D, et al. (2019) Inactivation of PP2A by a recurrent mutation drives resistance to MEK inhibitors. Oncogene |
| Taylor SE, O'Connor CM, Wang Z, et al. (2019) The highly recurrent PP2A Aα-subunit mutation P179R alters protein structure and impairs PP2A enzyme function to promote endometrial tumorigenesis. Cancer Research |
| Tohmé R, Izadmehr S, Gandhe S, et al. (2019) Direct activation of PP2A for the treatment of tyrosine kinase inhibitor-resistant lung adenocarcinoma. Jci Insight. 4 |
| Mazhar S, Taylor SE, Sangodkar J, et al. (2019) Targeting PP2A in cancer: Combination therapies. Biochimica Et Biophysica Acta. Molecular Cell Research. 1866: 51-63 |